Verve Therapeutics

Help us give a virtual high five to those celebrating five years at Verve. Thank you to Michael Amaonye, Angela C., Jamie DeNizio, PhD, Sekar (Sek) Kathiresan and Leslie Stolz for your commitment to Verve’s mission over the years and for helping to build this company from the ground up. Congratulate these Vervians by commenting with a 👏👏👏!

Taking time to recharge is crucial for fostering innovation and overall well-being. That's why our team will be taking a well-deserved summer shutdown break to relax, rejuvenate, and spend quality time with loved ones. We’ll be back on September 2!

Our Chief Scientific Officer Troy Lister will be speaking at the 2024 Genome Engineering: CRISPR Frontiers. He will be joining others in the genome engineering space to speak Verve's #geneediting treatments for #cardiovascular disease. Learn more about the event here: https://lnkd.in/eYhXxAKn #cshlcrispr24

When the cornhole boards come out, it’s game time. We love to compete, and there’s nothing more heated than our annual cornhole finals match. A big congrats to our finalists Matthew Greenfield and Ryan Garrity for giving it their all and to Matthew Schmidt, PharmD and Chelsey Jensen for winning gold for the second time. Until next year! 🥇

Headed to Canaccord Genuity's 44th Annual Growth Conference? Our co-founder and CEO Sekar (Sek) Kathiresan will be joining a fireside chat and highlighting our pipeline progress. Join us on Tuesday, August 13. https://lnkd.in/gE3PXDSW

Today, we announced pipeline progress and earnings from Q2 2024. Here's what you need to know: • The Heart-2 Phase 1b clinical trial of VERVE-102, a single course treatment intended to durably reduce disease-driving low-density lipoprotein cholesterol, is enrolling in the U.K. and Canada. The clinical trial application was recently cleared in Australia. • The Heart-2 and PCSK9 program data update is planned for the first half of 2025. • The Phase 1b clinical trial initiation for VERVE-201 is on track for the second half of 2024. • Strong cash position and runway expected into late 2026. For more information, read the full announcement here: https://lnkd.in/evy4dY_c

Ready to make your next career move to an innovative company developing #geneediting medicines for #cardiovascular disease? We are looking to add a Senior Scientist, Toxicologist to our growing team. Learn more from hiring manager Kimberly Pendino and check out the role here: https://lnkd.in/eYbaTwc7

Each year, we spend a day at Cathleen Stone Island for our annual summer outing, and it never disappoints! To feed our competitive itch, we held a corn hole competition and enjoyed the outdoor air all while enjoying our favorite snacks and refreshments. At Verve, we’re proud of the culture we’re creating.

It’s #NationalInternDay, and we’re excited to celebrate our team of interns! At Verve, we are passionate about advancing STEM education, and we are continually inspired by the curiosity, energy and fresh perspectives that our interns bring to the program. Thank you to this talented group for your contributions; together, we are shaping the future of #cardiovascular health.

We're excited to present our new series, #VerveVocab. In this bimonthly series, Verve team members will take complex scientific concepts and vocabulary related to #cardiovascular disease, #geneediting, and beyond, and make them crystal clear. First up, let's dive into "lipid nanoparticles," or in simpler terms, LNPs!